October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 16, 2025

New Criteria, New Numbers on Obesity

A Lancet Commission definition integrating BMI with anthropometric measures increased obesity prevalence by ~60% in a major US cohort, identifying previously unrecognized high-risk patients while introducing distinct clinical phenotypes.

Conexiant

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 07, 2025

EASO Issues Obesity Pharmacotherapy Guidance

EASO framework guides obesity drug selection by weight loss effect and complication focus.

Conexiant

October 06, 2025

Hypertension Drove Atrial Fibrillation Across Study Periods

Incidence rose 44% over three decades, with hypertension as primary driver in all periods

Conexiant

October 01, 2025

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."

Conexiant

September 29, 2025

Clinicians: Ultraprocessed Food Limits Coming to Cafeterias?

States consider bipartisan bans on ultraprocessed foods in schools over obesity and child health.

KFF Health News